Cargando…
Changes in Plasma IL-6, Plasma VEGF and Serum YKL-40 During Treatment with Etanercept and Methotrexate or Etanercept Alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
Changes in plasma IL-6, plasma VEGF and serum YKL-40 were determined in rheumatoid arthritis (RA) patients during treatment with etanercept alone or in combination with methotrexate. Twenty-five patients with active RA (DAS28 ≥ 3.2) were randomized to receive etanercept (25 mg sc. biweekly) plus met...
Autores principales: | Knudsen, Lene Surland, Hetland, Merete Lund, Johansen, Julia Sidenius, Skjødt, Henrik, Peters, Niels Daugaard, Colic, Ada, Grau, Karin, Nielsen, Hans Jørgen, Østergaard, Mikkel |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796864/ https://www.ncbi.nlm.nih.gov/pubmed/20029652 |
Ejemplares similares
-
Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012) -
Etanercept/methotrexate: COVID-19: case report
Publicado: (2020) -
Etanercept/methotrexate: Treatment failure: case report
Publicado: (2021) -
The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014) -
Effects of methotrexate and etanercept treatment in moderate and severe psoriasis
por: Benites, Elizabeth, et al.
Publicado: (2022)